News articles about Cesca Therapeutics (NASDAQ:KOOL) have been trending positive this week, Alpha One Sentiment Analysis reports. The research group, a service of Accern, rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Alpha One ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cesca Therapeutics earned a media sentiment score of 0.44 on Alpha One’s scale. Alpha One also assigned headlines about the biotechnology company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an impact on the company’s share price in the next several days.
Separately, Maxim Group restated a “hold” rating on shares of Cesca Therapeutics in a research note on Monday, March 20th.
Shares of Cesca Therapeutics (NASDAQ:KOOL) traded down 3.82% during mid-day trading on Friday, hitting $3.02. The stock had a trading volume of 23,653 shares. The company’s 50 day moving average price is $3.15 and its 200 day moving average price is $3.04. The stock’s market cap is $29.86 million. Cesca Therapeutics has a 12-month low of $2.41 and a 12-month high of $7.39.
Cesca Therapeutics (NASDAQ:KOOL) last announced its quarterly earnings results on Monday, February 13th. The biotechnology company reported ($0.35) earnings per share for the quarter. Cesca Therapeutics had a negative return on equity of 37.44% and a negative net margin of 297.49%. The business had revenue of $4.01 million for the quarter. Equities research analysts predict that Cesca Therapeutics will post ($4.52) EPS for the current fiscal year.
Cesca Therapeutics Company Profile
Cesca Therapeutics Inc is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/cesca-therapeutics-kool-receives-news-impact-score-of-0-44/1836915.html
Receive News & Ratings for Cesca Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.